My SNMMI Overview

My Organizations
My Councils
My Committees

Advanced Theranostics Tumor Board

Sponsored by the SNMMI Theranostics Leadership and Operations Group (TLOG) 

March 2026 - Case-Based Multidisciplinary Perspectives in Theranostics: Challenging and Emerging Clinical Scenarios

Tuesday, March 31, 2026 | 3:00 pm ET

Free for SNMMI Members

Join us for the monthly SNMMI Advanced Theranostics Tumor Board!

Organized by: Harshad R. Kulkarni, MD

Moderators: TBD 

Speakers:

Brandon R. Mancini, MD, MBA, FACRO, BAMF Health, Grand Rapids, MI

Srinivasa Chandana, MD, PhD, The Cancer and Hematology Centers, Grand Rapid, MI

Reserve Your Spot Today

Register Now

Summary:

This multidisciplinary theranostics tumor board will present complex oncology cases illustrating the clinical integration of molecular imaging and radiopharmaceutical therapy in patient management. Through structured case-based discussion, participants will explore practical approaches to patient selection, interpretation of molecular imaging findings, treatment sequencing, and assessment of therapeutic response. Molecular imaging will be considered both in the diagnostic setting, including PET, and in the post-therapy setting using SPECT/CT to inform response assessment and inter-cycle treatment decisions. As theranostic applications continue to evolve and expand through ongoing clinical investigation, this session will highlight how emerging evidence and multidisciplinary perspectives can be translated into effective, patient-centered strategies for contemporary oncologic care. This activity is intended for nuclear medicine physicians, medical oncologists, radiation oncologists, nuclear medicine technologists, advanced practice providers, and other healthcare professionals involved in molecular imaging and theranostic care.

Learning Objectives:

Upon completion of this session, participants will be able to:

  1. Evaluate the role of molecular imaging in identifying patients who may benefit from radiopharmaceutical therapies in established indications and emerging clinical trial settings.
  2. Analyze complex clinical scenarios using multidisciplinary perspectives to guide patient selection, treatment sequencing, and management decisions in theranostics.
  3. Integrate case-based evidence and expert discussion into clinical practice to improve patient-centered decision making in radiopharmaceutical therapy.

Who Should Attend:

This program is ideal for nuclear medicine physicians, technologists, oncologists, and other healthcare professionals involved in theranostics and targeted radionuclide therapy.

 

Upcoming Tumor Boards:

  • 2026 April – TBD 
  • 2026 May – University of Colorado 2026
  • 2026 June - Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan
  • 2026 July – Mount Sinai
  • 2026 August – Emory
  • 2026 September – New Mexico
  • 2026 October – Stanford
  • 2026 November – Harvard/Beth Isreal
  • 2026 December – MSKCC
  • 2027 January – United Theranostics

 

Past Tumor Boards:

    Interested in Presenting on a Future Advanced Theranostics Tumor Board?

    Sign-up to learn more and identify a month that works best for your institution. 

    Sign Up